title: [Preparation of two poor water soluble drugs - nanoporous ZnO solid dispersions and the mechanism of drug dissolution improvement].
abstract: Nanoporous ZnO was used as a carrier to prepare drug solid dispersion, the mechanism of which to improve the drug dissolution was also studied. Nanoporous ZnO, obtained through chemical deposition method, was used as a carrier to prepare indomethacin and cilostazol solid dispersions by melt-quenching method, separately. The results of scanning electron microscope, surface area analyzer, fourier transform infra-red spectroscopy, differential scanning calorimeter and X-ray diffraction showed that drugs were implanted into nanopores of ZnO by physical adsorption effect and highly dispersed into nanopores of ZnO in amorphous form, moreover, these nanopores strongly inhibited amorphous recrystallization in the condition of 45 degrees C and 75% RH. In addition, the results of the dissolution tested in vitro exhibited that the accumulated dissolutions of indomethacin and cilostazol solid dispersions achieved about 90% within 5 min and approximately 80% within 30 min. It was indicated in this study that the mechanism of drug dissolution improvement was associated with the effects of nanoporous ZnO carrier on increasing drug dispersion, controlling drug in nanopores as amorphous form and inhibiting amorphous recrystallization.
authors.affiliation: School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
authors.forename: Bei
authors.initials: B
authors.lastname: Gao
authors.forename: Chang-shan
authors.initials: CS
authors.lastname: Sun
authors.forename: Zhuang-zhi
authors.initials: ZZ
authors.lastname: Zhi
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Di
authors.initials: D
authors.lastname: Chang
authors.forename: Si-ling
authors.initials: SL
authors.lastname: Wang
authors.forename: Tong-ying
authors.initials: TY
authors.lastname: Jiang
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000737:chemistry; D002152:Calorimetry, Differential Scanning; D000077407:Cilostazol; D004337:Drug Carriers; D007213:Indomethacin / Q000008:administration & dosage / Q000737:chemistry; D008855:Microscopy, Electron, Scanning; D049329:Nanostructures; D058987:Phosphodiesterase 3 Inhibitors / Q000008:administration & dosage / Q000737:chemistry; D012995:Solubility; D017550:Spectroscopy, Fourier Transform Infrared; D013777:Tetrazoles / Q000008:administration & dosage / Q000737:chemistry; D014961:X-Ray Diffraction; D015034:Zinc Oxide / Q000737:chemistry*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004337:Drug Carriers; D058987:Phosphodiesterase 3 Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol; D015034:Zinc Oxide; D007213:Indomethacin